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Abstract
Background: Effective management of patients with chronic kidney disease (CKD) relies on timely detection of
clinical deterioration towards end stage kidney failure. We aimed to design an electronic Patient-Reported Outcome
Measure (ePROM) system, which would allow patients with advanced CKD (pre-dialysis) to: (i) remotely self-report
their symptoms using a simple and secure online platform; (ii) share the data with the clinical team in real-time via
the electronic patient record to help optimise care. We adopted a staged development process which included: a
systematic review of PROMs used in CKD; formation of a co-design team; prototype system design/development,
user acceptance testing and refinement; finalisation of the system for testing in a pilot/feasibility trial.
Results: A co-design team was convened, including patients with lived experience of CKD; clinical team members;
IT/Informatics experts; academics; and Birmingham Clinical Trials Unit representatives. A prototype system was
developed and iterative changes made before finalisation during a series of operational meetings. The system
allows patients to remotely self-report their symptoms; provides tailored self-management advice; allows
monitoring of real-time patient ePROM data; sends automated notifications to the patient/clinical team in the
advent of a severe symptom report; and incorporates longitudinal ePROM symptom data into the electronic patient
record. Feasibility of the system will be evaluated as part of the National Institute for Health Research funded
RePROM (Renal electronic Patient-Reported Outcome Measure) pilot trial (ISRCTN12669006).
Conclusions: Routine ePROM collection with real-time feedback has the potential to improve outcomes and
reduce health service costs. We have successfully developed a trial-ready ePROM system for advanced CKD, the
feasibility of which is currently being explored in a pilot trial. Assuming feasibility is demonstrated, formal evaluation
of efficacy will take place in a future multi-centre randomised controlled trial.
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Background
The global burden of chronic kidney disease (CKD) con-
tinues to increase, with age-standardised death and
disability-adjusted life years rising over recent decades
[1]. Patients with advanced CKD (pre-dialysis) com-
monly experience a high symptom burden and impaired
health-related quality of life, which represents a signifi-
cant driver of outcomes and can be a particular source
of anxiety [2–4].
With increasing use of digital healthcare, there has been
much interest in the potential of harnessing electronic
Patient-Reported Outcome Measures (ePROMs) to aid
the management of symptom burden and optimise use of
limited healthcare resources [5]. These measures allow pa-
tients to self-report their individual symptoms and overall
symptom burden remotely using online platforms, with
the opportunity to make the arising data available to
health professionals in real-time to help support care [6].
Evidence in an oncology setting suggests patients are
willing to complete ePROM symptom questionnaires on a
regular basis, and that the data can be integrated into the
electronic patient record (EPR), with beneficial results.
Studies in cancer populations suggest that ePROM symp-
tom monitoring may be associated with enhanced patient-
clinician communication and patient activation; earlier de-
tection of adverse events; improved patient quality of life;
reduced use of accident and emergency services; fewer in-
patient hospital episodes; and improved survival, even for
‘computer-inexperienced’ patients [7–14].
Whilst disease-specific PROMs are commonly used in
pre-dialysis renal research, for example the Kidney Disease
Quality of Life—36 (KDQOL- 36) and KDQOL-SF mea-
sures [15, 16], there has been relatively little research ex-
ploring the role of ePROMs in online renal symptom
monitoring. The feasibility of routine ePROM capture has
been demonstrated in patients with end stage kidney dis-
ease on home or in-centre dialysis, and in patients with
CKD stage 4/5 (pre-dialysis), but without real-time feed-
back of data [17, 18]. A multi-centre randomised con-
trolled trial (RCT) is therefore required to evaluate
ePROM use with real-time feedback and EPR data inte-
gration to determine if health professionals, providers and
policy-makers should implement systems in routine clin-
ical practice. Before a definitive trial is undertaken, the
Renal electronic Patient-Reported Outcome (RePROM)
pilot trial is being conducted to assess feasibility and de-
termine the key design elements for the full-scale RCT.
Here, we describe the development of the RePROM inter-
vention: an ePROM system for symptom monitoring in
patients with advanced CKD (pre-dialysis).
Methods
Development of the RePROM symptom reporting sys-
tem is reported according to the Criteria for Reporting
the Development and Evaluation of Complex Interven-
tions in healthcare: revised guideline (CReDECI 2) [19].
Setting
The RePROM study was undertaken within the Centre
for Patient-Reported Outcomes Research at the Univer-
sity of Birmingham and the Queen Elizabeth Hospital
Birmingham (QEHB) within the UK National Health
Service (NHS) University Hospitals Birmingham Foun-
dation Trust (UHBFT).
Patient and public involvement
Development of the study design was informed by a
series of meetings held with the study Patient Advisory
Group (PAG), which included people with lived experi-
ence of CKD. PAG members were recruited via a tar-
geted invitation distributed by renal staff at QEHB and
academic staff within the Centre for Patient-Reported
Outcome Research (CPROR) at the University of Bir-
mingham. Members contributed to the design of the
project prior to the application for funding, and the sub-
sequent refinement of the protocol and patient-facing
documentation, and were also involved in the ePROM
co-design group, as outlined below. The PAG received
compensation for their involvement in line with guide-
lines provided by the National Institute for Health Re-
search INVOLVE UK national advisory group (https://
www.invo.org.uk).
Underlying theoretical basis
Development of the ePROM system drew upon under-
pinning theory around the use of such data for the pur-
poses of clinical monitoring and the promotion of
enhanced patient-centred care, self-management and
clinical communication [20]. In particular, the theoret-
ical models of Greenhalgh [20–22] and others [23–26].
Which highlight the potential of PROMs as a tool to
support clinical management of patients, where patient-
centred instruments are used to continually feedback
data to all individuals involved in the care of the patient,
in a format that allows integration within existing clin-
ical data. We also sought to build a platform that might
conform to models describing the role of PROM data in
supporting: patient-clinician communication; shared un-
derstanding and decision-making; and optimal patient
self-management of symptoms [20, 27, 28].
The core co-design group set a four-fold remit for the
system:
1. To allow patients with advanced CKD to remotely
self-report their symptoms using a simple and
secure online platform.
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2. To provide appropriate self-management advice to
patients whose ePROM scores highlighted one or
more mild/moderate/severe symptoms.
3. To allow monitoring of real-time patient ePROM
symptom data and subsequent automated
notification of both the patient and the clinical team
in the advent of a severe symptom report.
4. To incorporate longitudinal ePROM symptom data
in the EPR to help inform clinical consultations and
foster shared understanding/decision-making.
Design components
A staged development process was adopted, which in-
cluded: a systematic review of PROMs used in CKD; for-
mation of a co-design team; prototype system design/
development, user acceptance testing and refinement;
and finalisation of the system for use in the RePROM
pilot/feasibility trial.
A systematic review of the literature, reported else-
where [29], was undertaken to explore the measurement
properties of PROMs used in adult patients with CKD
and inform development of the ePROM system. Screen-
ing of 3702 titles/abstracts yielded 66 papers meeting
the eligibility criteria, which described 25 PROMs. Three
disease-specific PROMs were used in pre-dialysis popu-
lations: Agarwal [30], KDQOL- 36 [31, 32] and KDQOL-
SF [33, 34]. There was evidence to support some satis-
factory measurement properties (Agarwal: limited evi-
dence for test-retest reliability and content validity;
KDQOL-SF: moderate evidence for test-retest reliability
and hypothesis testing; KDQOL-36: strong evidence for
internal consistency, moderate evidence for hypothesis
testing). However, these tools were missing evidence to
support many other important properties (Agarwal: in-
ternal consistency, measurement error, structural valid-
ity, hypothesis testing, responsiveness; KDQOL-SF:
internal consistency, measurement error, content valid-
ity, structural validity, responsiveness; KDQOL-36: reli-
ability, measurement error, content validity, structural
validity, responsiveness). In addition, none of the mea-
sures had been validated in a UK pre-dialysis population.
In parallel, a co-design team was convened, compris-
ing: patients with lived experience of CKD (n = 6) and
cancer (n = 1), who were members of the study patient
advisory group; members of the broader renal clinical
team at QEHB (n = 7), UHBFT IT/Informatics experts
(n = 3); academics (n = 3); and members of the Birming-
ham Clinical Trials Unit (BCTU) (n = 5). In addition, de-
sign input was sought from international ePROM
experts Profs Ethan Basch (University of North Carolina,
United States), Niels Hjöllund (Arhuus University,
Denmark) and Galina Velikova (Patient Outcomes
Group, University of Leeds, United Kingdom).
User acceptance testing of a prototype version of the
system, described in detail elsewhere [35], was con-
ducted with 8 adult patients with advanced CKD (stages
4/5); the average usability and satisfaction score was 4.6
(5-point scale). Iterative changes were made to the sys-
tem in response to the findings as outlined below.
Our initial intention was to incorporate an existing,
validated, PROM within the final system. However, as
outlined above, the systematic review failed to identify a
valid, reliable, responsive and non-burdensome measure
suitable for symptom monitoring in a UK pre-dialysis
population [29]. The PAG and clinical members of the
co-design group were therefore unable to select an exist-
ing validated measure which captured information on all
identified patient- and clinician-important symptoms,
without potentially burdening end- users with multiple
questionnaires containing duplicate items. In order to
proceed with feasibility testing of the ePROM system,
we therefore developed stand-alone symptom-based
questionnaire items based on the core actionable symp-
toms identified by our patient advisory group members
and the UHBFT renal clinical team. In addition, the for-
mat and presentation of both the questions and response
options was altered to increase font size and aid read-
ability. Most questions were also allocated to a single
page of the questionnaire to enhance clarity. A flag was
added to highlight unanswered mandatory questions and
a progress bar inserted as a point of reference for ques-
tionnaire completion to facilitate user orientation. De-
sign of the ePROM system was finalised during a series
of operational meetings held with the co-design team in
2017–2018.
Results
System architecture
The final system architecture is shown in Fig. 1. Patients
access the ePROM system via the existing QEHB patient
portal ‘myHealth’, which sits behind the NHS firewall.
Approximately 20,000 patients with various conditions
who receive care at QEHB are signed up to myHealth.
These patients are able to use myHealth to access out-
patient appointment details, test results and consultant
correspondence.
A bespoke software programme, ‘DataCollector’, was
built by a senior developer from the Application Devel-
opment team at University Hospitals NHS Foundation
Trust. DataCollector includes a ‘back end’ administrative
section used to build ePROM questionnaires and display
the data and a ‘front end’ which enables patients to view
and complete questionnaires, and to view their longitu-
dinal ePROM data over time, all within myHealth. Data-
Collector was developed using Microsoft. Net
technology, mainly ASP. Net Webforms, C#, Entity
framework and SQL Server. As with myHealth, all data
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are stored on secure servers behind the NHS trust
firewall.
User interaction
A myHealth reminder system is tasked to send monthly
emails to patients asking them to complete and submit
an ePROM questionnaire. However, patients are able to
submit any number of additional ‘ad-hoc’ questionnaires
at any time outside of the scheduled monthly reporting
dates.
After logging in to myHealth, patients are able to
complete the ePROM online in approximately 6–10min
(see Fig. 2 for system screenshots). The ePROM directs
patients to submit regular self-reports across a range of
symptoms commonly experienced in CKD, including: fa-
tigue; shortness of breath; loss of appetite; nausea or
vomiting; itchiness or dry skin; pain; problems with fis-
tula; faintness or dizziness; difficulty sleeping; restless
legs; diarrhoea and ankle swelling. The questionnaire
also includes an open text item which allows patients to
report any other symptoms or problems that they would
like to flag to their kidney care team.
Both patients and clinicians are able to view identical
graphical and tabulated views of patient’s longitudinal
ePROM report data, either remotely online (patients) or
via the EPR (clinicians). This identical view was sug-
gested by both patients and clinicians in the co-design
team as an essential feature aimed at fostering a shared
understanding of the patient’s symptom burden.
A system algorithm highlights severe symptoms that
may require clinical follow-up, delivering pertinent in-
formation to the patient via an on screen ‘pop-up’, and
sending an automated email to the kidney care team
containing details of the symptom(s) triggering the noti-
fication and providing a direct link with which to access
all of the patient’s ePROM reports (Fig. 1).
Feasibility piloting and evaluation
Feasibility of the system will be evaluated as part of the
National Institute for Health Research (NIHR) funded
RePROM (Renal electronic Patient-Reported Outcome
Measure) pilot trial (reference: PDF-2016-09-009). A
protocol for the study is available [36]. The full methods
and results will be published following completion.
In summary, the RePROM pilot trial is an investigator
led, single-centre, open-label, two-arm randomised con-
trolled pilot trial of 66 participants aged 18 years or over
with advanced CKD (trial definition: estimated Glomeru-
lar Filtration rate (eGFR) ≥6 and ≤ 15mL/min/1.73m2
inclusive; or a projected risk of progression to end-stage
renal failure within 2-years ≥20% using the 4-variable
Tangri renal risk calculator [37]). The trial is registered
with ISRCTN (ISRCTN12669006) and the NIHR Portfo-
lio (CPMS ID: 36497). The study schema is outlined in
Fig. 3.
The primary aims of the study are to pilot the trial
protocol and assess the feasibility of undertaking a full-
scale RCT exploring the use of an ePROM in the
Fig. 1 Overview of RePROM system architecture
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management of advanced CKD. This will include assess-
ment of both quantitative and qualitative data. The pilot
study will:
 Test and pilot the trial protocol (including
recruitment and retention rates, data collection
processes, data completeness and adherence to the
ePROM intervention);
 Assess the willingness of clinicians to randomise
participants into the trial;
 Assess the willingness of people with advanced CKD
to be randomised into the trial;
 Assess the acceptability of the ePROM system;
 Explore the need for a non-web-based intervention
platform for participants who are unable to use the
online ePROM;
 Inform selection of the most appropriate primary
outcome measure for the full-scale RCT;
 Provide data to help estimate the sample size for the
full-scale RCT;
 Provide a platform to develop and pilot the
processes to capture costs and outcomes to inform
the health economic evaluation for the full-scale
RCT;
 Determine key participation criteria for centre
involvement in the full-scale RCT.
A range of trial outcomes will be captured 3, 6, 9 and
12-months post randomisation (assessment window +/−
3 weeks). These include clinical data e.g.: Serum Creatin-
ine, Calcium, Phosphate, Bicarbonate, Albumin, eGFR,
Albumin Creatinine Ratio, blood pressure, and for par-
ticipants with diabetes: glucose and HbA1c. Patient qual-
ity of life will be assessed using a paper version of the
EQ-5D-5L questionnaire, a reliable/validated generic
measure of health status commonly used in CKD trials
research [38]. Healthcare resource use data will also be
collected, adopting a NHS/personal social care primary
perspective, which will focus on healthcare resource use
and costs including: renal staff activity in response to
Fig. 2 RePROM system example screenshots (dummy data). a myHealth home screen; b RePROM question page; c tabulated raw questionnaire
data and d graphical display of longitudinal ePROM data, patient/clinician view identical; e tailored advice provided to patients upon submission
of a questionnaire; f example of automated email notification sent to the kidney care team in response to a patient report of severe and
current fatigue
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ePROM notifications; GP and hospital consultations; in-
patient hospitalisation; medications; referrals; and NHS
costs associated with maintenance of the ePROM sys-
tem. Resource use will be valued using appropriate unit
costs such as the British National Formulary and the
most recent version of Unit Costs of Health and Social
Care and NHS Reference Costs [39]. Integrity/perform-
ance of the ePROM system technology will be explored
using both quantitative compliance data (including the
proportion of expected forms returned), notification case
report forms (detailing the cause of notification, clinical
response and time taken to address) and qualitative
debriefing interviews conducted with approximately 40
patients and clinicians/study personnel purposively se-
lected to capture those individuals who experienced a
range of outcomes and experiences during the trial
where possible.
Discussion
We have successfully developed an ePROM system
which allows patients with advanced CKD to remotely
self-report their symptoms using a simple and secure
online platform. The system integrates symptom data
into the hospital EPR and: (i) allows real-time monitor-
ing aimed at facilitating optimal care; (ii) includes auto-
mated self-management advice for patients; and (iii) can
trigger automated notification of both the patient and
the clinical team in the advent of a severe symptom
report.
To date, research exploring ePROM efficacy has pri-
marily focused on cancer. Basch and colleagues con-
ducted an RCT in the US, involving patients receiving
outpatient chemotherapy for advanced solid tumours;
with participants in the intervention arm asked to report
12 common symptoms on a weekly basis using the web-
based STAR (Symptom Tracking and Reporting)
ePROM system [12]. Four important findings emerged
from this work. First, significantly more patients in the
STAR arm experienced a clinically meaningful improve-
ment in health-related quality of life at 6 months, with
significantly fewer patients experiencing a clinically
meaningful deterioration. Second, ePROM use was asso-
ciated with fewer accident and emergency visits and in-
patient hospitalisations. Third, overall survival was
significantly improved in this group (median difference
5 months; median follow-up 7 years; hazard ratio 0.83,
95% CI, 0.70 to 0.99) [11]. Fourth, contact between nurs-
ing staff and patients in both arms of the study was simi-
lar, suggesting smooth integration of the ePROM system
into routine practice. In addition, resources used to
manage ePROM email alerts were modest, with the ma-
jority of cases resolved following telephone counselling
regarding symptom management.
A survival benefit was replicated in a similar ePROM
RCT, conducted by Denis et al., in a cohort of patients
undergoing treatment for lung cancer in France using
the ‘e-FAP’ (e-Follow-Up Application) (median survival
difference 7.6 months; 2 year follow-up; hazard ratio,
Fig. 3 RePROM pilot trial schema
Kyte et al. Journal of Patient-Reported Outcomes            (2020) 4:55 Page 6 of 9
0.59 95% CI, 0.37 to 0.96) [13, 14]. Again, perceived re-
source use was minimal, with a mean of 15 min weekly
spent by the oncologist to manage all web alerts (n = 60
simultaneous users). Moreover, this study was the first
to evaluate cost-effectiveness of an ePROM-based symp-
tom monitoring approach (average annual cost €362
lower per patient in the ePROM arm; €20,912 total cost
per Quality Adjusted Life Year) [40].
Both the STAR and e-FAP systems appeared to facili-
tate early detection of symptom deterioration and sup-
portive care needs, improving patient outcomes and
offering health provider/societal cost savings. In theory,
such a system could lead to similar benefits in a CKD
population, where effective management relies on the
timely detection of clinical deterioration towards end
stage kidney failure [41].
Feasibility of ePROM capture in patients with CKD
has been demonstrated in Canada and the UK. Schick-
Makaroff and Molzahn successfully used tablet com-
puters to capture ePROM data from n = 99 patients on
attendance at outpatient home dialysis clinics in two cit-
ies on the west coast of Canada over a 6-month time-
frame [18]. Pittman et al. collected daily ePROM data
from 43 UK patients with CKD stage 4/5 (19 receiving
haemodialysis, 5 receiving peritoneal dialysis, and 19
pre-dialysis) [17]. Eighty percent submitted data for > 30
days, with 65% continuing daily submission up to 90
days. However, neither study appeared to incorporate
real-time data upload to an EPR, or automated patient/
clinician feedback and notifications, both key compo-
nents of the STAR and e-FAP systems [12, 13].
Our system has adopted these additional real-time fea-
tures and is currently being evaluated in the RePROM
pilot trial in a pre-dialysis population. We intend to ex-
plore the experiences of patients using RePROM, com-
pared to those documented using the aforementioned
ePROM systems in renal disease [17, 18] and cancer [12,
13]. Assuming feasibility is demonstrated, and after any
necessary refinements, the final RePROM system will be
included in a planned multi-centre RCT.
Limitations
As mentioned, our co-design group were unable to en-
dorse an existing, validated, PROM for use within our
system as planned. Systematic review demonstrated that
renal PROMs frequently lacked validation in English-
speaking populations (particularly in the UK) and were
missing evidence to support important measurement
properties including measurement error, structural val-
idity, responsiveness and patient acceptability [29].
There is a need to develop a renal ePROM that mini-
mises questionnaire burden whilst optimising precision
and which demonstrates appropriate validity, reliability,
responsiveness and acceptability to be used at an
individual patient level in the NHS. Thus, we are cur-
rently in the process of developing and validating a for-
mal renal symptom item bank, computerised adaptive
testing system and paper-based short-form (Kidney Re-
search UK funding, ref.: KS_RP_013_20180914), which
will be incorporated into the existing ePROM system
prior to evaluation in a RCT. Whilst incorporation of
the ePROM within a pre-existing hospital patient portal
allowed us to take advantage of inbuilt security features,
constraints within the portal system meant we were un-
able to implement a telephone-based interactive voice
recognition feature to support patients with limited on-
line access, as we had initially planned. In addition, at
the time of implementation, the portal was not opti-
mised for smartphone usage, a potential barrier to access
that we intend to explore in the process evaluation phase
of the feasibility study.
Conclusions
Routine ePROM collection and real-time feedback in pa-
tients with advanced CKD has the potential to improve
outcomes and reduce health service costs. We have suc-
cessfully developed a trial-ready ePROM system, the
feasibility of which is currently being explored in a pilot
study. An updated system, incorporating a validated
renal symptom item bank currently in development, will
be subjected to evaluation in a future UK-based multi-
centre RCT.
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